Aerie Pharmaceuticals, Inc. (AERI)
Chart Events
Performance Outlook
| Previous Close | 18.41 |
| Open | 17.35 |
| Bid | 18.18 x 1200 |
| Ask | 18.24 x 800 |
| Day's Range | 18.05 - 18.43 |
| 52 Week Range | 9.01 - 21.30 |
| Volume | 33,601 |
| Avg. Volume | 712,815 |
| Market Cap | 847.792M |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.99 |
| Earnings Date | Feb 25, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.25 |
- Business Wire
Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 12:45 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
- Business Wire
Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the publication of a peer-reviewed paper in eLife, a science journal, entitled, "Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis." This paper evaluates the treatment effect of netarsudil, marketed as Rhopressa® (netarsudil ophthalmic solution) 0.02% in the United States, on steroid-induced ocular hypertension in a mouse model and steroid-induced glaucoma in humans.
- Zacks
Aerie (AERI) Up 11.8% Since Last Earnings Report: Can It Continue?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
